```
=> d his nofile

     (FILE 'HOME' ENTERED AT 12:17:20 ON 24 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 12:17:33 ON 24 OCT 2006
L1                STRUCTURE UPLOADED
L2              0 SEA SSS SAM L1
                  D QUE L1

     FILE 'STNGUIDE' ENTERED AT 12:17:56 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 12:18:42 ON 24 OCT 2006
L3                STRUCTURE UPLOADED
L4              3 SEA SSS SAM L3
L5                STRUCTURE UPLOADED
                  D QUE L5
L6              0 SEA SSS SAM L5

     FILE 'STNGUIDE' ENTERED AT 12:21:53 ON 24 OCT 2006

     FILE 'CAPLUS' ENTERED AT 12:22:51 ON 24 OCT 2006
                  E US2006-569812/APPS
L7              1 SEA ABB=ON  PLU=ON  US2006-569812/AP
                  D SCAN
                  SEL RN L7

     FILE 'REGISTRY' ENTERED AT 12:23:15 ON 24 OCT 2006
L8             45 SEA ABB=ON  PLU=ON  (107-82-4/BI OR 126747-14-6/BI OR 127152-98
                  -1/BI OR 14199-15-6/BI OR 156-38-7/BI OR 1647-26-3/BI OR
                  18162-48-6/BI OR 1878-68-8/BI OR 27727-37-3/BI OR 33155-58-7/BI
                   OR 335200-36-7/BI OR 5292-43-3/BI OR 5437-45-6/BI OR 55784-09-
                  3/BI OR 845785-97-9/BI OR 845785-98-0/BI OR 845785-99-1/BI OR
                  845786-00-7/BI OR 845786-01-8/BI OR 845786-02-9/BI OR 845786-03
                  -0/BI OR 845786-04-1/BI OR 845786-06-3/BI OR 845786-07-4/BI OR
                  845786-08-5/BI OR 845786-09-6/BI OR 845786-10-9/BI OR 845786-11
                  -0/BI OR 845786-12-1/BI OR 845786-13-2/BI OR 845786-14-3/BI OR
                  845786-15-4/BI OR 845786-16-5/BI OR 845786-17-6/BI OR 845786-18
                  -7/BI OR 845786-19-8/BI OR 845786-20-1/BI OR 845786-21-2/BI OR
                  845786-22-3/BI OR 845786-23-4/BI OR 845786-24-5/BI OR 845786-25
                  -6/BI OR 845786-26-7/BI OR 845786-27-8/BI OR 98946-18-0/BI)
                  D SCAN

     FILE 'REGISTRY' ENTERED AT 12:42:18 ON 24 OCT 2006
L*** DEL6429975 S NR=3
L*** DEL        0 S L*** AND O3/ELS AND N1/ELS
L*** DEL        0 S L*** AND O3/ELS
L*** DEL        0 S L*** AND 3O/ELS
                  D HIE

     FILE 'STNGUIDE' ENTERED AT 12:45:24 ON 24 OCT 2006
L9              0 SEA ABB=ON  PLU=ON  L*** AND NH2/ELS
L10             0 SEA ABB=ON  PLU=ON  L*** AND 2HN/ELS
L11             0 SEA ABB=ON  PLU=ON  L*** AND NH2
L12             0 SEA ABB=ON  PLU=ON  L*** AND NH2/ESS

     FILE 'STNGUIDE' ENTERED AT 12:46:27 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 12:47:42 ON 24 OCT 2006
L13               STRUCTURE UPLOADED
```

```
L14          50 SEA SUB=L*** SSS SAM L13

     FILE 'STNGUIDE' ENTERED AT 12:48:21 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 12:49:45 ON 24 OCT 2006
L15               STRUCTURE UPLOADED
L16            0 SEA SUB=L*** SSS SAM L15
                  D QUE L15
L17               STRUCTURE UPLOADED
L18            4 SEA SUB=L*** SSS SAM L17
                  D QUE L17
L19            4 SEA SSS SAM L17
                  D SCAN
                  D QUE L17

     FILE 'STNGUIDE' ENTERED AT 12:53:54 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:00:08 ON 24 OCT 2006
L20               STRUCTURE UPLOADED
L21           29 SEA SSS SAM L20

     FILE 'STNGUIDE' ENTERED AT 13:01:54 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:03:31 ON 24 OCT 2006
L22               STRUCTURE UPLOADED
L23            9 SEA SSS SAM L22

     FILE 'STNGUIDE' ENTERED AT 13:03:53 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:05:19 ON 24 OCT 2006
L24               STRUCTURE UPLOADED
L25            1 SEA SSS SAM L24
                  D SCAN

     FILE 'STNGUIDE' ENTERED AT 13:05:42 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:06:20 ON 24 OCT 2006
L26               STRUCTURE UPLOADED
L27            5 SEA SSS SAM L26

     FILE 'STNGUIDE' ENTERED AT 13:06:48 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:08:33 ON 24 OCT 2006
L28               STRUCTURE UPLOADED
L29           50 SEA SSS SAM L28
                  D QUE L28
L30               STRUCTURE UPLOADED
L31            6 SEA SSS SAM L30

     FILE 'STNGUIDE' ENTERED AT 13:10:10 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:11:44 ON 24 OCT 2006
L32               STRUCTURE UPLOADED
L33            6 SEA SSS SAM L32

     FILE 'STNGUIDE' ENTERED AT 13:12:02 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:15:51 ON 24 OCT 2006
L34               STRUCTURE UPLOADED
```

```
L35             6 SEA SSS SAM L34

     FILE 'STNGUIDE' ENTERED AT 13:16:09 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 13:18:15 ON 24 OCT 2006

     FILE 'STNGUIDE' ENTERED AT 13:19:56 ON 24 OCT 2006
                D QUE L34

     FILE 'REGISTRY' ENTERED AT 14:30:29 ON 24 OCT 2006
L36             6 SEA SSS SAM L34
                D SCAN

     FILE 'STNGUIDE' ENTERED AT 14:31:05 ON 24 OCT 2006
                D SCAN L8

     FILE 'REGISTRY' ENTERED AT 14:31:37 ON 24 OCT 2006
                D SCAN L8
L37             3 SEA ABB=ON  PLU=ON  L8 AND C17H14N2O3/MF
                D SCAN
                D L37 IDE
L*** DEL      118 S RID

     FILE 'STNGUIDE' ENTERED AT 14:41:14 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 14:43:31 ON 24 OCT 2006
L38             STRUCTURE UPLOADED
L39             2 SEA SSS SAM L38

     FILE 'STNGUIDE' ENTERED AT 14:43:56 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 14:55:37 ON 24 OCT 2006
L40             STRUCTURE UPLOADED
L41             0 SEA SSS SAM L40

     FILE 'STNGUIDE' ENTERED AT 14:55:54 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 14:57:05 ON 24 OCT 2006
L42             STRUCTURE UPLOADED
L43             9 SEA SSS SAM L42
                D QUE L42
L44          1518 SEA SSS FUL L42
                SAVE L44 LAO812/A TEMP
L45             9 SEA ABB=ON  PLU=ON  L44 AND L8
L46            36 SEA ABB=ON  PLU=ON  L8 NOT L45
                D SCAN
                D SCAN L43

     FILE 'STNGUIDE' ENTERED AT 15:03:47 ON 24 OCT 2006

     FILE 'REGISTRY' ENTERED AT 15:04:55 ON 24 OCT 2006
L47             STRUCTURE UPLOADED
L48             0 SEA SUB=L44 SSS SAM L47
L49             9 SEA SUB=L44 SSS FUL L47

     FILE 'HCAPLUS' ENTERED AT 15:05:26 ON 24 OCT 2006
L50             5 SEA ABB=ON  PLU=ON  L49

     FILE 'REGISTRY' ENTERED AT 15:05:44 ON 24 OCT 2006
```

```
               D SCAN L49

     FILE 'BEILSTEIN' ENTERED AT 15:07:31 ON 24 OCT 2006
L51              STRUCTURE UPLOADED
L52            1 SEA SSS FUL L51
L53            1 SEA ABB=ON  PLU=ON  L52 NOT L49

     FILE 'MARPAT' ENTERED AT 15:08:31 ON 24 OCT 2006
L54           18 SEA SSS SAM L47
L55          348 SEA SSS FUL L47
L56          345 SEA ABB=ON  PLU=ON  L55/COM
L57           15 SEA SUB=L55 SSS SAM L51
L58          293 SEA SUB=L55 SSS FUL L51

     FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 OCT 2006

     FILE 'MARPAT' ENTERED AT 15:10:15 ON 24 OCT 2006
L59              STRUCTURE UPLOADED
L60           11 SEA SUB=L55 SSS SAM L59
L61          174 SEA SUB=L55 SSS FUL L59

     FILE 'STNGUIDE' ENTERED AT 15:10:55 ON 24 OCT 2006

     FILE 'MARPAT' ENTERED AT 15:11:53 ON 24 OCT 2006
L62              STRUCTURE UPLOADED
L63            9 SEA SUB=L55 SSS SAM L62

     FILE 'STNGUIDE' ENTERED AT 15:12:18 ON 24 OCT 2006

     FILE 'MARPAT' ENTERED AT 15:13:16 ON 24 OCT 2006
L64              STRUCTURE UPLOADED
L65            9 SEA SUB=L55 SSS SAM L64

     FILE 'STNGUIDE' ENTERED AT 15:13:43 ON 24 OCT 2006

     FILE 'MARPAT' ENTERED AT 15:14:19 ON 24 OCT 2006
L66              STRUCTURE UPLOADED
L67            9 SEA SUB=L55 SSS SAM L66

     FILE 'STNGUIDE' ENTERED AT 15:14:42 ON 24 OCT 2006

     FILE 'MARPAT' ENTERED AT 15:15:55 ON 24 OCT 2006
L68              STRUCTURE UPLOADED
L69            7 SEA SUB=L55 SSS SAM L68
L70          103 SEA SUB=L55 SSS FUL L68
L71          101 SEA ABB=ON  PLU=ON  L70/COM

     FILE 'REGISTRY' ENTERED AT 15:16:49 ON 24 OCT 2006

     FILE 'HCAPLUS' ENTERED AT 15:17:01 ON 24 OCT 2006
L72          420 SEA ABB=ON  PLU=ON  L44
L73          113 SEA ABB=ON  PLU=ON  L44 (L) (THU OR PAC OR BAC OR PKT OR
                 DMA)/RL
L74           86 SEA ABB=ON  PLU=ON  L73 AND (PY<2003 OR AY<2003 OR PRY<2003)
                 E INFLAMMATORY DISEASE/CT
                 E E3+ALL
                 E E2+ALL
L75       196219 SEA ABB=ON  PLU=ON  INFLAMMATION+OLD,PFT,RT,NT/CT
                 E AUTOIMMUNE /CT
```

```
                E E8+ALL
L76         43307 SEA ABB=ON  PLU=ON  "AUTOIMMUNE DISEASE"+OLD,PFT,RT,NT/CT
L77        295902 SEA ABB=ON  PLU=ON  (INFLAMM? OR AUTOIMMUN? OR AUTO(1A)IMMUN?)/
                OBI,BI
L78            18 SEA ABB=ON  PLU=ON  L74 AND (L75 OR L76)
L79            20 SEA ABB=ON  PLU=ON  L74 AND L77
L80            22 SEA ABB=ON  PLU=ON  (L78 OR L79)
L81            23 SEA ABB=ON  PLU=ON  (L7 OR L80)
L82           420 SEA ABB=ON  PLU=ON  (L7 OR L72)
L83           113 SEA ABB=ON  PLU=ON  (L7 OR L73)
L84            87 SEA ABB=ON  PLU=ON  (L7 OR L74)
                D KWIC L80
                D KWIC L80 2
L85            31 SEA ABB=ON  PLU=ON  L73 AND (L75 OR L76 OR L77)
L86            31 SEA ABB=ON  PLU=ON  (L85 OR L80)

     FILE 'STNGUIDE' ENTERED AT 15:21:22 ON 24 OCT 2006

     FILE 'HCAPLUS' ENTERED AT 15:22:04 ON 24 OCT 2006
                E HOLMES/CT
                E HOLMES/AU
                E HOLMES I/AU
L87           103 SEA ABB=ON  PLU=ON  ("HOLMES I"/AU OR "HOLMES I B"/AU OR
                "HOLMES I F"/AU OR "HOLMES I H"/AU OR "HOLMES I P"/AU OR
                "HOLMES IAN"/AU OR "HOLMES IAN B"/AU OR "HOLMES IAN D"/AU OR
                "HOLMES IAN F"/AU OR "HOLMES IAN H"/AU OR "HOLMES IAN HAMILTON"
                /AU OR "HOLMES IAN P"/AU OR "HOLMES IAN PETER"/AU)
                E WATSON S/AU
L88            94 SEA ABB=ON  PLU=ON  ("WATSON S"/AU OR "WATSON S P"/AU)
                E WATSON S/AU
L89             8 SEA ABB=ON  PLU=ON  ("WATSON STEFAN"/AU OR "WATSON STEPHEN"/AU)

                E WATSON STE/AU
L90           224 SEA ABB=ON  PLU=ON  ("WATSON STEPHEN P"/AU OR "WATSON STEPHEN
                PAUL"/AU OR "WATSON STEVE P"/AU)
                E WATSON STE/AU
L91             3 SEA ABB=ON  PLU=ON  "WATSON STEVEN P"/AU
L92             4 SEA ABB=ON  PLU=ON  L87 AND (L88 OR L89 OR L90 OR L91)
L93             6 SEA ABB=ON  PLU=ON  (L87 OR L88 OR L89 OR L90 OR L91 OR L92)
                AND (L75 OR L76 OR L77)
L94             6 SEA ABB=ON  PLU=ON  (L92 OR L93)
                D QUE L49
L95             3 SEA ABB=ON  PLU=ON  L49 AND (PY<2003 OR AY<2003 OR PRY<2003)
                D BIB
L96            30 SEA ABB=ON  PLU=ON  L86 NOT L94
L97             4 SEA ABB=ON  PLU=ON  L49 NOT L94
L98             6 SEA ABB=ON  PLU=ON  (L94 OR L7)

=> file hcaplus
FILE 'HCAPLUS' ENTERED AT 15:26:19 ON 24 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 24 Oct 2006 VOL 145 ISS 18
FILE LAST UPDATED: 23 Oct 2006 (20061023/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> d que l94
L75      196219 SEA FILE=HCAPLUS ABB=ON  PLU=ON  INFLAMMATION+OLD,PFT,RT,NT/CT

L76       43307 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "AUTOIMMUNE DISEASE"+OLD,PFT,R
                T,NT/CT
L77      295902 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (INFLAMM? OR AUTOIMMUN? OR
                AUTO(1A)IMMUN?)/OBI,BI
L87         103 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("HOLMES I"/AU OR "HOLMES I
                B"/AU OR "HOLMES I F"/AU OR "HOLMES I H"/AU OR "HOLMES I P"/AU
                OR "HOLMES IAN"/AU OR "HOLMES IAN B"/AU OR "HOLMES IAN D"/AU
                OR "HOLMES IAN F"/AU OR "HOLMES IAN H"/AU OR "HOLMES IAN
                HAMILTON"/AU OR "HOLMES IAN P"/AU OR "HOLMES IAN PETER"/AU)
L88          94 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("WATSON S"/AU OR "WATSON S
                P"/AU)
L89           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("WATSON STEFAN"/AU OR
                "WATSON STEPHEN"/AU)
L90         224 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("WATSON STEPHEN P"/AU OR
                "WATSON STEPHEN PAUL"/AU OR "WATSON STEVE P"/AU)
L91           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "WATSON STEVEN P"/AU
L92           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L87 AND (L88 OR L89 OR L90 OR
                L91)
L93           6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L87 OR L88 OR L89 OR L90 OR
                L91 OR L92) AND (L75 OR L76 OR L77)
L94           6 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L92 OR L93)


=> d ibib abs l94 tot

L94  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:395279  HCAPLUS <<LOGINID::20061024>>
DOCUMENT NUMBER:          142:447210
TITLE:                    Preparation of heterocyclic compounds for treating
                          conditions mediated by EP1 receptor and TxA2 receptor
INVENTOR(S):              Giblin, Gerard Martin Paul; Hall, Adrian; Hurst, David
                          Nigel; Lewell, Xiao Qing; Lorthioir, Olivier Eric;
                          McKeown, Stephen Carl; Scoccitti, Tiziana;
                          Watson, Stephen Paul
PATENT ASSIGNEE(S):       Glaxo Group Limited, UK
SOURCE:                   PCT Int. Appl., 66 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

BR 9609782	A	19990309	BR 1996-9782	19960711	<--
JP 11511124	T2	19990928	JP 1996-505989	19960711	<--
NZ 312950	A	20000128	NZ 1996-312950	19960711	<--
EE 3694	B1	20020415	EE 1997-362	19960711	<--
EE 200200384	A	20021015	EE 2002-384	19960711	<--
PL 188446	B1	20050228	PL 1996-324491	19960711	<--
IL 122783	A1	20050831	IL 1996-122783	19960711	<--
TW 570927	B	20040111	TW 1996-85108493	19960712	<--
FI 9800033	A	19980305	FI 1998-33	19980109	<--
NO 9800097	A	19980311	NO 1998-97	19980109	<--
BG 63876	B1	20030430	BG 1998-102241	19980210	<--
US 6239108	B1	20010529	US 1998-983391	19980810	<--
US 6596687	B1	20030722	US 2000-482296	20000113	<--
AU 758886	B2	20030403	AU 2000-36445	20000525	<--
US 6875743	B1	20050405	US 2000-724139	20001128	<--
PRIORITY APPLN. INFO.:			US 1995-498237	A 19950711	<--
			AU 1996-64894	A3 19960711	<--
			WO 1996-US11570	W 19960711	<--
			US 1998-983391	A1 19980810	<--

OTHER SOURCE(S): MARPAT 126:199840

AB The present invention relates to novel peptide derivs. that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compds. and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compds. and pharmaceutical composition of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many ***inflammatory*** and ***autoimmune*** diseases. Thus, coupling of 4-(2-MeC6H4NHCONH)C6H4CH2CO2H (preparation given) with protected peptide H-Leu-Asp(OCH2Ph)-Val-OCH2Ph (preparation given), followed by catalytic hydrogenolysis, gave cell adhesion inhibitor peptide 4-(2-MeC6H4NHCONH)C6H4CH2CO-Leu-Asp-Val-OH (I). All 408 prepared peptide derivs., including I, inhibited VLA4-dependent adhesion to a bovine serum albumin conjugate with H-Cys-Tyr-Asp-Glu-Leu-Pro-Gln-Leu-Val-Thr-Leu-Pro-His-Pro-Asn-Leu-His-Gly-Pro-Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr-OH, with IC50 values of <1 mM.

IC ICM C07K014-78
ICS C07K005-02; C07K005-06; C07K005-08; C07K005-10; A61K038-04; A61K038-39

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

ST peptide prepn cell adhesion inhibitor; antiinflammatory drug peptide deriv prepn; ***autoimmune*** disease treatment peptide deriv prepn

IT ***Anti-inflammatory agents***
Autoimmune disease
(preparation of peptide derivs. as cell adhesion inhibitors)

187736-24-9P	187736-25-0P	187736-26-1P	187736-27-2P	187736-28-3P
187736-29-4P	187736-30-7P	187736-31-8P	187736-32-9P	187736-33-0P
187736-34-1P	187736-35-2P	187736-36-3P	187736-37-4P	187736-38-5P
187736-39-6P	187736-40-9P	187736-41-0P	187736-42-1P	187736-43-2P
187736-44-3P	187736-45-4P	187736-46-5P	187736-47-6P	187736-48-7P
187736-49-8P	187736-50-1P	187736-51-2P	187736-52-3P	187736-53-4P
187736-54-5P	187736-55-6P	187736-56-7P	187736-57-8P	187736-58-9P
187736-59-0P	187736-60-3P	187736-61-4P	187736-62-5P	187736-63-6P
187736-64-7P	187736-65-8P	187736-66-9P	187736-67-0P	187736-68-1P
187736-69-2P	187736-70-5P	187736-71-6P	187736-72-7P	187736-73-8P
187736-74-9P	187736-75-0P	187736-76-1P	187736-77-2P	187736-78-3P
187736-79-4P	187736-80-7P	187736-81-8P	187736-82-9P	187736-83-0P
187736-84-1P	187736-85-2P	187736-86-3P	187736-87-4P	187736-88-5P

187736-89-6P 187736-90-9P 187736-91-0P 187736-92-1P 187736-93-2P
187736-94-3P 187736-95-4P 187736-96-5P 187736-97-6P 187736-98-7P
187736-99-8P 187737-00-4P 187737-01-5P 187737-02-6P 187737-03-7P
187737-04-8P 187737-05-9P 187737-06-0P 187737-07-1P 187737-08-2P
187737-09-3P 187737-10-6P 187737-11-7P 187737-12-8P 187737-13-9P
187737-15-1P 187737-17-3P 187737-18-4P 187737-19-5P
187737-21-9P 187737-23-1P 187737-26-4P 187737-28-6P
187737-31-1P 187737-33-3P 187737-34-4P 187737-35-5P 187737-36-6P
187737-38-8P 187737-39-9P 187737-40-2P 187737-41-3P 187737-42-4P
187737-43-5P 187737-44-6P 187737-45-7P 187737-46-8P 187737-47-9P
187737-48-0P 187737-49-1P 187737-50-4P 187737-51-5P 187737-52-6P
187737-53-7P 187737-54-8P 187737-55-9P 187737-56-0P 187737-57-1P
187737-59-3P 187737-60-6P 187737-61-7P 187737-62-8P 187737-63-9P
187737-64-0P 187737-65-1P 187737-66-2P 187737-67-3P 187737-68-4P
187737-69-5P 187737-70-8P 187737-71-9P 187737-72-0P 187737-73-1P
187737-74-2P 187737-75-3P 187737-76-4P 187737-77-5P 187737-78-6P
187737-79-7P 187737-80-0P 187737-81-1P 187737-82-2P 187737-83-3P
187737-84-4P 187737-85-5P 187737-86-6P 187737-87-7P 187737-88-8P
187737-89-9P 187737-90-2P 187737-91-3P 187737-92-4P 187737-93-5P
187737-94-6P 187737-95-7P 187737-96-8P 187737-97-9P 187737-98-0P
187737-99-1P 187738-00-7P 187738-01-8P 187738-02-9P 187738-03-0P
187738-04-1P 187738-05-2P 187738-06-3P 187738-07-4P 187738-08-5P
187834-08-8P
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide derivs. as cell adhesion inhibitors)

IT ***187737-21-9P 187737-23-1P***
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); ***THU (Therapeutic use)***; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide derivs. as cell adhesion inhibitors)

RN 187737-21-9 HCAPLUS
CN 1-Pyrrolidinepropanoic acid, β-[[[1-(methoxycarbonyl)-2-methylpropyl]amino]carbonyl]-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, [1[S(S)]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187737-23-1 HCAPLUS

CN 1-Pyrrolidinepropanoic acid, 3-[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]-β-[[[1-(methoxycarbonyl)-2-methylpropyl]amino]carbonyl]-2-oxo-, [1[S(S)]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L96 ANSWER 30 OF 30 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:214381 HCAPLUS <<LOGINID::20061024>>
DOCUMENT NUMBER: 106:214381
TITLE: [(Hydroxycarbamoyl)alkanoyl]amino acid derivatives as collagenase inhibitors
INVENTOR(S): Dickens, Jonathan Philip; Donald, David Keith; Kneen, Geoffrey; McKay, William Roger
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: Eur. Pat. Appl., 70 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 214639	A2	19870318	EP 1986-112386		19860908	<--
EP 214639	A3	19880217				
EP 214639	B1	19900613				
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE						
US 4599361	A	19860708	US 1985-774491		19850910	<--
US 4743587	A	19880510	US 1986-880130		19860707	<--
AT 53573	E	19900615	AT 1986-112386		19860908	<--
PRIORITY APPLN. INFO.:			US 1985-774491	A	19850910	<--
			US 1986-880130	A	19860707	<--
			EP 1986-112386	A	19860908	<--

GI



HOHNCOXCONHCHR^{2}CONHR^1 I R^{5}COCH$_2$CH(CH$_2$CHMe$_2$)CONHCHCONMe II

AB The title compds. [I; R1 = alkyl; R2 = alkyl, (substituted) PhCH2; X = CHR3CHR4, R3C:CR4; R3 = H, alkyl, Ph, phenylalkyl; R4 = H, alkyl, phenylalkyl, cycloalkyl, cycloalkylalkyl] were prepared as collagenase inhibitors. Me2CHCH2COCO2H was coupled with O-methyl-L-tyrosine methylamide using (COCl)2 and DMF in CH2Cl2. The product ketone was olefinated with PhCH2O2CCH2P(O)(OMe)2 followed by hydrogenation to give a mixture of 2 acyltyrosine derivs. II (R5 = HO). These were converted to II (R5 = HONH) (III) by successive treatment with EtO2CCl and H2NOH.HCl. One isomer of III inhibited human rheumatoid synovial collagenase with an IC50 of 0.02 μM.

IC ICM C07C103-50
ICS C07C103-58; A61K037-64

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

IT ***Inflammation*** inhibitors
(antiarthritics, hydroxamic acid derivs.)

IT 104408-38-0P 104408-39-1P 104408-52-8P ***104408-53-9P***
104408-54-0P 104408-55-1P 104408-59-5P 104408-60-8P 104408-61-9P
104485-71-4P 104485-72-5P 104485-73-6P 108383-51-3P 108383-52-4P
108383-53-5P 108383-54-6P 108383-55-7P 108383-56-8P 108383-57-9P
108383-58-0P 108383-59-1P 108383-60-4P 108383-61-5P 108383-62-6P
108383-63-7P 108383-64-8P 108383-65-9P 108383-66-0P 108383-67-1P
108383-68-2P 108383-69-3P 108383-70-6P 108383-71-7P 108383-72-8P
108383-73-9P 108383-78-4P
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as collagenase inhibitor)

IT ***104408-53-9P***
RL: ***BAC (Biological activity or effector, except adverse)***; BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as collagenase inhibitor)

RN 104408-53-9 HCAPLUS

CN Butanediamide, N1-hydroxy-N4-[1-[(4-methoxyphenyl)methyl]-2-(methylamino)-2-oxoethyl]-3-(2-methylpropyl)-2-phenyl- (9CI) (CA INDEX NAME)



```
=> file beils
FILE 'BEILSTEIN' ENTERED AT 15:27:22 ON 24 OCT 2006
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON JUNE 16, 2006

FILE COVERS 1771 TO 2006.
*** FILE CONTAINS  9,606,495 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                 *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE    *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE           *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                         *
* FOR PRICE INFORMATION SEE HELP COST                                 *
**********************************************************************
    NEW
* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE
  SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,
  ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A
  COMPOUND AT A GLANCE.

=> d que l53
L42             STR
```

Beilstein

N [1]



G1 O, [@1]

Structure attributes must be viewed using STN Express query preparation.
L44 1518 SEA FILE=REGISTRY SSS FUL L42
L47 STR



Structure attributes must be viewed using STN Express query preparation.
L49 9 SEA FILE=REGISTRY SUB=L44 SSS FUL L47
L51 STR



Structure attributes must be viewed using STN Express query preparation.
L52 1 SEA FILE=BEILSTEIN SSS FUL L51
L53 1 SEA FILE=BEILSTEIN ABB=ON PLU=ON L52 NOT L49

=> d ide allref l53 tot

L53 ANSWER 1 OF 1 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

Beilstein Records (BRN):	3390730
Chemical Name (CN):	3-bicyclohexyl-4-yl-succinamic acid ethyl ester
Autonom Name (AUN):	3-bicyclohexyl-4-yl-succinamic acid ethyl ester
Molec. Formula (MF):	C18 H31 N O3
Molecular Weight (MW):	309.45
Lawson Number (LN):	11110, 298
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	3040392
Tautomer ID (TAUTID):	3247640
Beilstein Citation (BSO):	3-09-00-04036
Entry Date (DED):	1990/02/15
Update Date (DUPD):	1992/06/02



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
MP	Melting Point	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Fieser et al., J.Amer.Chem.Soc., CODEN: JACSAT, 70, <1948>, 3177

=> file marpat
FILE 'MARPAT' ENTERED AT 15:27:43 ON 24 OCT 2006

FILE CONTENT: 1961-PRESENT VOL 145 ISS 17 (20061020/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	7108861	19 SEP 2006
DE	102005009517	31 AUG 2006
EP	1696501	30 AUG 2006
JP	2006228955	31 AUG 2006
WO	2006091896	31 AUG 2006
GB	2423301	23 AUG 2006
FR	2882363	25 AUG 2006
RU	2282647	27 AUG 2006
CA	2547866	22 AUG 2006

Expanded G-group definition display now available.

=> d que l71
L47 STR



Structure attributes must be viewed using STN Express query preparation.
L55 348 SEA FILE=MARPAT SSS FUL L47
L68 STR



Structure attributes must be viewed using STN Express query preparation.
L70 103 SEA FILE=MARPAT SUB=L55 SSS FUL L68
L71 101 SEA FILE=MARPAT ABB=ON PLU=ON L70/COM

=> d ibib abs qhit l71 81-101

L71 ANSWER 81 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 124:232069 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of arylsulfonylaminomethylhydroxamic acids and related compounds as matrix metalloproteinase inhibitors.
INVENTOR(S): Miller, Andrew; Whittaker, Mark; Beckett, Raymond Paul
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535276	A1	19951228	WO 1995-GB1465	19950622
W: AU, BR, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2193691	AA	19951228	CA 1995-2193691	19950622
CA 2193692	AA	19951228	CA 1995-2193692	19950622
AU 9527466	A1	19960115	AU 1995-27466	19950622
AU 690703	B2	19980430		
GB 2303850	A1	19970305	GB 1996-23675	19950622
GB 2303850	B2	19980610		
EP 766665	A2	19970409	EP 1995-922639	19950622
EP 766665	B1	19990728		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1151157	A	19970604	CN 1995-193714	19950622
JP 10507158	T2	19980714	JP 1995-501848	19950622
AT 182581	E	19990815	AT 1995-922639	19950622

ES 2133785	T3	19990916	ES 1995-922639	19950622
ES 2145913	T3	20000716	ES 1995-922638	19950622
PT 766664	T	20000831	PT 1995-922638	19950622
FI 9605153	A	19961220	FI 1996-5153	19961220
US 6022898	A	20000208	US 1996-765146	19961223
US 6124332	A	20000926	US 1999-243130	19990203
US 6124329	A	20000926	US 1999-343087	19990630
PRIORITY APPLN. INFO.:			GB 1994-12514	19940622
			GB 1995-6107	19950324
			WO 1995-GB1465	19950622

GI



AB XR1CHNR2(YZ) [X = CO2H, CONHOH; R1 = (protected) amino acid side chain; R2 = Z1QW; Z1 = H, (substituted) aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl; QW = bond; or Q = O, S; W = (O-, S- or imino-interrupted) (substituted) alkylene, alkenylene; or Q = bond; Y = SO2; Z = (substituted) aryl, heteroaryl], were prepared as metalloproteinase inhibitors (no data). I and 16 similar compds. were prepared

MSTR 1



G3 = biphenylyl
G4 = alkylene <containing 1-8 C>
(opt. substd. by 1 or more G13)
G13 = CO2H / CONH2
G27 = 5

G4—G3
5 10

Derivative: or salts, hydrates, or solvates
Patent location: claim 1

L71 ANSWER 82 OF 101 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 123:227994 MARPAT <<LOGINID::20061024>>
TITLE: Heterocyclic derivatives as platelet aggregation inhibitors
INVENTOR(S): Wayne, Michael Garth; Smithers, Michael James; Rayner, John Wall; Faull, Alan Wellington; Pearce, Robert James; Brewster, Andrew George; Shute, Richard Eden; Mills, Stuart Dennett; Caulkett, Peter William Rodney
PATENT ASSIGNEE(S): Zeneca Ltd., UK
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422834	A1	19941013	WO 1994-GB647	19940328
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2156070	AA	19941013	CA 1994-2156070	19940328
AU 9462889	A1	19941024	AU 1994-62889	19940328
AU 692438	B2	19980611		
EP 691959	A1	19960117	EP 1994-910494	19940328
EP 691959	B1	19980722		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9406613	A	19960206	BR 1994-6613	19940328
HU 72088	A2	19960328	HU 1995-2290	19940328
CN 1120334	A	19960410	CN 1994-191664	19940328
JP 08508291	T2	19960903	JP 1994-521810	19940328
EP 825184	A1	19980225	EP 1997-117909	19940328
EP 825184	B1	20010620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 168678	E	19980815	AT 1994-910494	19940328
ES 2119184	T3	19981001	ES 1994-910494	19940328
RU 2142944	C1	19991220	RU 1995-122602	19940328
IL 109144	A1	20000229	IL 1994-109144	19940328
AT 202345	E	20010715	AT 1997-117909	19940328
ES 2159798	T3	20011016	ES 1997-117909	19940328
PT 825184	T	20011130	PT 1997-117909	19940328
FI 9504616	A	19950928	FI 1995-4616	19950928
NO 9503837	A	19950928	NO 1995-3837	19950928
US 5750754	A	19980512	US 1996-658097	19960604
GR 3036640	T3	20011231	GR 2001-401498	20010918
PRIORITY APPLN. INFO.:			GB 1993-6453	19930329
			GB 1993-25605	19931215
			GB 1993-6451	19930329
			GB 1993-25610	19931215
			EP 1994-910494	19940328
			WO 1994-GB647	19940328
			GB 1995-18188	19950907

GI



I

AB Pyridine derivs. and metabolically labile esters and amides thereof were disclosed as pharmaceuticals. The compds. are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. A specifically claimed compound is 4-[2-[4-(4-pyridinyl)-1-piperazinyl]acetyl]phenoxyacetic acid (I).

MSTR 1



G13 = 45-8 46-6



G15 = phenylene
G28 = 8-9 7-6



G30 = alkylene <containing 1-4 C> (opt. substd. by G37)
G37 = CO2H
G43 = NH2 (opt. substd.)
Derivative: and pharmaceutically acceptable salts
Patent location: claim 1
Note: substitution is restricted

MSTR 4



G13 = 45-8 46-6

G14—G15
45 46

G15 = phenylene
G28 = 8-9 7-6

G1——G13
8 7

G30 = alkylene <containing 1-4 C> (opt. substd. by G37)
G37 = CO2H
G43 = NH2 (opt. substd.)
Derivative: or acid addition salts
Patent location: claim 17
Note: substitution is restricted

L71 ANSWER 83 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 122:315098 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of peptide analogs as fibrinogen receptor antagonists
INVENTOR(S): Egbertson, Melissa S.; Turchi, Laura M.; Hartman, George D.; Halczenko, Wasyl; Whitman, David B.; Perkins, James J.; Krause, Amy E.; Ihle, Nathan; Claremon, David Alan; et al.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9412181	A1	19940609	WO 1993-US11623	19931129
W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2150550	AA	19940609	CA 1993-2150550	19931129
AU 9458268	A1	19940622	AU 1994-58268	19931129
AU 675689	B2	19970213		
EP 673247	A1	19950927	EP 1994-904069	19931129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08504194	T2	19960507	JP 1993-513464	19931129
US 5648368	A	19970715	US 1995-448347	19950601
PRIORITY APPLN. INFO.:			US 1992-984671	19921201
			WO 1993-US11623	19931129

GI



I

AB X-Y-Z-Ar-A-B [X = NR1R2, NR1C(:NR2)R1, (substituted) 4-10 membered mono- or polycyclic (aromatic) ring, etc.; R1-R3 = H, alkyl, cycloalkyl, arylalkyl, aminoalkyl, hydroxyalkyl, etc.; Y = alkylene, cycloalkylene, Y1NR3COY1, etc.; Y1 = C0-8 alkyl; Z, A = (CH2)m, (CH2)mO(CH2)n, (CH2)mNR3(CH2)n, (CH2)mSO2(CH2)n, etc.; Ar = (substituted) 6-membered monocyclic aromatic ring containing 0-4 N atoms; B = CR6R7COR12, CR8R9CR10R11(CH2)pCOR12; R7-R11 = H, F, hydroxyalkyl, carboxyalkyl, alkoxy, cycloalkyl, dialkylaminoalkyl, arylalkylaminosulfonylalkyl, etc.; p = 0, 1; R12 = OH, alkoxy, alkylcarbonyloxyalkoxy, amino acid residue, etc.; with provisos], were prepared Title compound I was prepared by solution phase coupling methods. Preferred title compds. inhibited platelet aggregation with IC50 = 0.009-170 μM.

MSTR 1A

G6—G9—G1—G10—G25
1 37 4 5 6

G1 = phenylene
G9 = 182-1 183-4

H_2C—p-C_6H_4
182 183

G10 = 2-4 3-6

G11—C(O)
2 3

G11 = carbon chain <0 or more double bonds, 0 or more triple bonds> (opt. substd. by G12)
G12 = CONH2
G25 = OH
Derivative: and pharmaceutically acceptable salts
Patent location: claim 1

MSTR 1B



G1 = phenylene
G9 = p-C6H4
G10 = 2-4 3-6



G11 = carbon chain <0 or more double bonds, 0 or more triple bonds> (opt. substd. by G12)
G12 = CONH2
G25 = OH
Derivative: and pharmaceutically acceptable salts
Patent location: claim 1

L71 ANSWER 84 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 122:268205 MARPAT <<LOGINID::20061024>>
TITLE: Electrocoat-base coat-clear coat finishes stabilized with S-triazine UV absorbers
INVENTOR(S): Stevenson, Tyler A.; Holt, Mark S.; Ravichandran, Ramanathan
PATENT ASSIGNEE(S): Ciba-Geigy Corp., USA
SOURCE: U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 12,699, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5354794	A	19941011	US 1994-189627	19940201
CA 2152169	AA	19940818	CA 1994-2152169	19940202
CA 2152169	C	20050517		
ES 2215996	T3	20041016	ES 1994-907964	19940202
US 5476937	A	19951219	US 1994-268093	19940628
JP 2004352728	A2	20041216	JP 2004-243626	20040824
PRIORITY APPLN. INFO.:			US 1993-12699	19930203
			US 1994-189627	19940201
			JP 1994-518217	19940202

AB A polymer film composition comprises (a) an electro coat primer in adhesion to a metal substrate; (b) a base or color coat that is in adhesion to the electro coat and which comprises a film-forming binder and an organic pigment or an inorg. pigment or mixture thereof; (c) a clear coat that is in adhesion to the base coat and which comprises a film-forming binder; and (d) an effective stabilizing amount of ≥1 tris-aryl-s-triazine UV absorber contained in either the base coat or the clear coat or in both base coat and clear coat. The tris-aryl-s-triazine UV absorbers provide excellent light stability protection to electro coat, base coat or clear

coat finishes. A typical UV absorber was 2,4,6-tris[2-hydroxy 4-(2-hydroxy-3-nonyloxypropoxy)phenyl]-s-triazine and was used in a high solids thermoset acrylic coating.

MSTR 1



G1 = 28



G2 = alkyl <containing 1-24 C>
(opt. substd. by (1-8) G3)
G3 = biphenylyl (opt. substd. by (1-3) G4) / 38



G15 = O / 36



Patent location: claim 3
Note: alkyl group in G2 may be additionally interrupted
Note: G21's are the same

L71 ANSWER 85 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 122:240447 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of peptideamide analogs as tachykinin antagonists.
INVENTOR(S): Pieper, Helmut; Austel, Volkhard; Jung, Birgit; Buerger, Erich; Entzeroth, Michael
PATENT ASSIGNEE(S): Karl Thomas GmbH, Germany

SOURCE: Ger. Offen., 101 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4243858	A1	19940630	DE 1992-4243858	19921223

PRIORITY APPLN. INFO.: DE 1992-4243858 19921223
GI



I

AB R4R5NACONHCHR3CXNR1R2 [A = 1,2-cyclopentylene, CHR6; R6 = H, (substituted) alkyl, Ph; R1 = H, (Ph- or pyridyl-substituted) alkyl; R2 = H, (amino- or guanidino-substituted) Ph, pyridyl, (cyclohexyl-, Ph-, or pyridyl-substituted) alkyl, etc.; R1R2N = (substituted) piperazinyl; R3 = H, (phenyl)alkyl, guanidino- or amino-substituted alkyl, aminocarbonylalkyl, etc.; R4 = H, (phenyl)alkyl; R5 = protecting group, (substituted) alkyl, alkanoyl, alkoxycarbonyl, alkylaminocarbonyl, PhCO, naphthylcarbonyl, biphenylcarbonyl, PhSO2, etc.; X = (H, H), O, S; the C atom bearing the R3 substituent is L; the C atom bearing the R6 substituent is D or L], were prepared Thus, title compound I (prepared by solution phase methods) showed IC50 = 2 nM for neurokinin-1 receptor binding with IM-9 cells. Tablets were prepared containing I.

MSTR 2

G1—G6

G1 = alkylcarbonyl <containing 1-9 C>
(opt. substd. by G2)
G2 = biphenylyl / CONH2
G6 = OH
Patent location: claim 11
Note: substitution is restricted

L71 ANSWER 86 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 122:85335 MARPAT <<LOGINID::20061024>>
TITLE: Fluorine-containing aromatic hydrocarbons for lubricating oils
INVENTOR(S): Sanechika, Kenichi; Ikeda, Chiho; Ikeda, Masanori
PATENT ASSIGNEE(S): Asahi Chemical Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06287578	A2	19941011	JP 1993-101804	19930406

PRIORITY APPLN. INFO.: JP 1993-101804 19930406

AB The oils comprise aromatic hydrocarbons of formula RR1n, in which (R = C6-60 arene; n = 1-4; R1 = C1-25 (partially stabilized) fluorohydrocarbyl having an atomic ratio of F/C ≥0.6). The oils show compatibility with fluoroalkane refrigerants.

MSTR 1A

G1 = 238



G2 = hydrocarbyl <containing 1-25 C>
(substd. by 1 or more G4)
G4 = CONH2 / CO2H
G7 = 240-2 242-239



G8 = phenylene
G9 = phenylene
G10 = bond
Patent location: claim 1

L71 ANSWER 87 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 122:82078 MARPAT <<LOGINID::20061024>>
TITLE: Cyclic peptide antifungal agents and process for preparation thereof
INVENTOR(S): Burkhardt, Frederick Joseph; Debono, Manuel; Nissen, Jeffrey Scott; Turner, William Wilson, Jr.

PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 561639	A1	19930922	EP 1993-302064	19930318
EP 561639	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2091663	AA	19930920	CA 1993-2091663	19930315
ZA 9301830	A	19940915	ZA 1993-1830	19930315
IL 105048	A1	20010614	IL 1993-105048	19930315
NZ 299314	A	20010928	NZ 1993-299314	19930315
CZ 288974	B6	20011017	CZ 1993-416	19930315
IL 122315	A1	20020310	IL 1993-122315	19930315
NZ 512085	A	20030829	NZ 1993-512085	19930315
NO 9300948	A	19930920	NO 1993-948	19930316
BR 9301232	A	19930921	BR 1993-1232	19930318
HU 63637	A2	19930928	HU 1993-785	19930318
CN 1080926	A	19940119	CN 1993-103587	19930318
CN 1036715	B	19971217		
JP 06056892	A2	19940301	JP 1993-58529	19930318
JP 3519754	B2	20040419		
RU 2129562	C1	19990427	RU 1993-4787	19930318
AT 217635	E	20020615	AT 1993-302064	19930318
JP 2002226500	A2	20020814	JP 2002-3969	19930318
JP 3520071	B2	20040419		
PT 561639	T	20021031	PT 1993-302064	19930318
ES 2174843	T3	20021116	ES 1993-302064	19930318
AU 9335341	A1	19930923	AU 1993-35341	19930319
AU 9665529	A1	19961205	AU 1996-65529	19960909
AU 689391	B2	19980326		
JP 2004115540	A2	20040415	JP 2003-412638	20031210

PRIORITY APPLN. INFO.: US 1992-854117 19920319
US 1992-992390 19921216
IL 1993-105048 19930315
JP 1993-58529 19930318

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. (I; R, R11 = independently H, OH; R1 = H, OH, OSO3H; R2 = substituted PhCO, biphenylyl, naphthoyl, etc.; R7 = R1, phosphonooxy; R8 = H, Me, H2NCOCH2; R9, R10 = Me, H), were prepared Thus, I (R = R7 = R11 = OH, R1 = H, R2 = Q1, R8 = R9 = R10 = Me), prepared by enzymic deacylation and then reacylation of echinocandin B, showed ED50 = 0.84 mg/mL for controlling systemic fungal infections in mice. Several I were effective against Pneumocystis carinii in immunosuppressed rats. I in general exhibit oral bioavailability.

MSTR 1



G6 = 85

C(O)-G12—G15
85 89

G12 = 86-85 88-89

G37—G13—G14
86 88

G13 = bond
G14 = phenylene
G15 = alkynyl <containing 2-12 C>
(opt. substd. by (1-2) G16)
G16 = CO2H / CONH2
G37 = phenylene
Derivative: or pharmaceutically acceptable non-toxic salts
Patent location: claim 2

L71 ANSWER 88 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 120:217717 MARPAT <<LOGINID::20061024>>
TITLE: Quinazoline inhibitors of HIV reverse transcriptase
INVENTOR(S): Lyle, Terry A.; Tucker, Thomas J.; Wiscount, Catherine M.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

Belist.

marpat
L71
88 of 101

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 569083	A1	19931110	EP 1993-201232	19930429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
WO 9322292	A1	19931111	WO 1993-US3975	19930428
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9342204	A1	19931129	AU 1993-42204	19930428
EP 639184	A1	19950222	EP 1993-910860	19930428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 71401	A2	19951128	HU 1994-3187	19930428
CA 2095194	AA	19931108	CA 1993-2095194	19930429
AU 9338413	A1	19931111	AU 1993-38413	19930506
CN 1085550	A	19940420	CN 1993-107074	19930506
ZA 9303179	A	19941107	ZA 1993-3179	19930506
JP 06009578	A2	19940118	JP 1993-107015	19930507
JP 08013805	B4	19960214		
FI 9405199	A	19941104	FI 1994-5199	19941104
NO 9404208	A	19950106	NO 1994-4208	19941104
PRIORITY APPLN. INFO.:			US 1992-880119	19920507
			US 1992-991164	19921216
			WO 1993-US3975	19930428

GI



I



II

AB The title compds. I [G = halogen, NO2, CN; R1 = C3-5 cycloalkyl, C2-5 alkynyl, C2-4 alkenyl, CN; R2 = substituted C2-5 alkynyl, substituted C2-5 alkenyl; R3 = H, CN, NH2, HO, (un)substituted C1-4 alkyl, (un)substituted C2-4 alkenyl, (un)substituted C2-4 alkynyl; R4 = H, C1-4 alkyl, C1-5 alkylcarbonyl, (un)substituted benzoyl, etc.; n = 0-4], useful in the treatment of AIDS and AIDS-related complex via the inhibition of HIV reverse transcriptase, are prepared Thus, quinazoline II was prepared (m.p. 119-121°) and demonstrated 50% HIV reverse transcriptase inhibitory concentration 13 mM.

MSTR 1



G3 = alkynyl <containing 2-5 C>
(opt. substd. by 1 or more G4)
G4 = 24 / biphenylyl

24 C(O)-G9

G9 = OH / NH2
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: substitution is restricted

L71 ANSWER 89 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 120:191426 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of antibacterial 1-normon-2-yl thiazolyl ketones
INVENTOR(S): Forrest, Andrew Keith; Pons, Jean Esther; O'Hanlon, Peter John
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9315072	A1	19930805	WO 1993-GB126	19930120
W: AT, AU, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, RO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9333613	A1	19930901	AU 1993-33613	19930120
EP 623130	A1	19941109	EP 1993-902425	19930120
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 07503244	T2	19950406	JP 1993-513016	19930120
CN 1088926	A	19940706	CN 1993-102064	19930121
ZA 9300481	A	19931116	ZA 1993-481	19930122
PRIORITY APPLN. INFO.:			GB 1992-1506	19920124
			GB 1992-15889	19920725
			WO 1993-GB126	19930120

GI



I

AB Title compds. [I; R1 = (substituted) alkoxy] were prepared Thus, 2-methoxythiazole in THF at -78° was treated with BuLi and then with N-methoxy-N-methyl-6,7,13-O-tris-(trimethylsilyl)monamide to give a residue which was stirred with HCl in THF to give I (R1 = OMe). I inhibited H. influenzae Q1, B. catarrhalis 1502, S. pyogenes CN10, S. pneumoniae PU7, and S. aureus Oxford with MIC's of 0.06-4 mg/mL.

MSTR 1



G1 = alkoxy <containing 1-10 C>
(opt. substd. by 1 or more G2)
G2 = CO2H / CONH2 / Ph (opt. substd. by (1-5) G4)
G4 = Ph
Patent location: claim 1

MSTR 3



G1 = alkoxy <containing 1-10 C>
(opt. substd. by 1 or more G2)
G2 = CO2H / CONH2 / Ph (opt. substd. by (1-5) G4)

G4 = Ph
Patent location: claim 8

MSTR 5



G1 = alkoxy <containing 1-10 C>
(opt. substd. by 1 or more G2)
G2 = CO2H / CONH2 / Ph (opt. substd. by (1-5) G4)
G4 = Ph
Patent location: claim 8

L71 ANSWER 90 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 120:107042 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of pyrimidocycloalkanes as angiotensin II antagonists and antihyperlipidemics.
INVENTOR(S): Primeau, John Laurent; Garrick, Lloyd Michael; Ocain, Timothy Donald; Soll, Richard Michael; Dollings, Paul Jeffrey
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9308171	A1	19930429	WO 1992-US8992	19921023
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
US 5234936	A	19930810	US 1991-782017	19911024
AU 9331228	A1	19930521	AU 1993-31228	19921023
EP 610439	A1	19940817	EP 1992-925019	19921023
EP 610439	B1	19991215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
AT 187717	E	20000115	AT 1992-925019	19921023
PRIORITY APPLN. INFO.:			US 1991-782017	19911024
			WO 1992-US8992	19921023

GI



I



II

AB Title compds. [I; X = H, NR12R13, OR14, cyano, F, Cl, iodo, Br, (perfluoro)alkyl, hydroxyalkyl, alkoxyalkyl, (CH)nCO2R14, (CH2)nCONR12R13; Y = NR15, NR18CR16R17, CR16R17NR15; R1 = 5-tetrazolyl, CO2R14, SO3H, NHSO2Me, NHSO2CF3; R2, R3 = X, aralkyl, NO2, SO2R19; R4-R11 = H, F, alkyl, alkoxyalkyl, OCOR14, hydroxylalkyl, perfluoroalkyl, aralkyl, aryl, cyano, NO2, SO2R19, (CH2)n(O2R14, (CH2)nCONR12R13, OH, OR14, NR12R13, or any 2 geminal groups can = O, CH2; R12, R13 = H, alkyl, aralkyl; R14 = H, alkyl, aralkyl, alkoxyalkyl; R5 = H, alkyl, (CH2)nCO2R14, alkoxyalkyl, aralkyl, (CH2)nCONR12R13, OR14, perfluoroalkyl, hydroxyalkyl, COR14, CONR12R13; R16, R17 = H, alkyl, alkoxyalkyl, hydroxyalkyl, perfluoroalkyl, aralkyl, cyano, NO2, SO2R19, (CH2)nCO2R14, (CH2)nCONR12R13; R18 = H, alkoxyalkyl, hydroxyalkyl, perfluoroalkyl, aralkyl, OR14, (CH2)nCO2R14, (CH2)nCONR12R13, alkyl, COR14, CONR12R13; R19 = (ar)alkyl; n = 0-3; m = 1-5], were prepared Thus, 2-ethoxycarbonylcyclohexanone was cyclocondensed with trifluoroacetamidine to give 57% 5,6,7,8-tetrahydro-2-trifluoromethyl-4-quinazolone, which was 4-chlorinated with POCl3 in dimethylaniline at reflux. The product was condensed with 4'-aminomethyl-1,1'-biphenyl-2-ylcarboxylic acid using NaOAc in refluxing BuOH to give title compound II. A specific I at 3 mg/kg id reduced angiotensin II-dependent blood pressure in rats by 45% 1/2 h after administration. I at 100-200 mg/kg orally in rats typically gave a 50% drop in total cholesterol.

MSTR 1



G6 = (0-3) CH2
G7 = OH / 32



G8 = 44-1 45-3 / 46-1 47-3

G11 = 56



G16 = 77-2 74-4 76-5



G17 = 89-3 88-6 84-7



G27 = alkylidene (opt. substd. by G11)
Derivative: and pharmaceutically acceptable salts
Patent location: claim 1
Note: additional ring derivatives allowed

L71 ANSWER 91 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 119:234022 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of sulfonylphthalimides as inhibitors of platelet-derived growth factor.
INVENTOR(S): Clader, John W.; Davis, Harry R.; Mullins, Deborra; Rosenblum, Stuart; Weinstein, Jay
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5238950	A	19930824	US 1991-808997	19911217

PRIORITY APPLN. INFO.: US 1991-808997 19911217
GI



I

AB The sulfonylphthalimides I [R = (un)substituted Ph or naphthyl, etc., R1 = NO2, NH2, BzNH, etc., n = 0,1] and related compds. are prepared as platelet-derived growth factor (PDGF) inhibitors, useful for the treatment of atherosclerosis, cancer, retinal detachment, etc. (no data). 2-Methyl-5-chlorobenzenesulfonolamide (preparation given) was refluxed with phthaloyl chloride, in toluene, to give I(R = 2-methyl-5-chlorophenyl, R1n= H)(II). II inhibited the binding of PDGF to PDGF receptors on human fibroblasts.

MSTR 1A



G1 = Ph (opt. substd. by (1-5) G2)
G2 = Ph
G14 = 13



G16 = alkylene (opt. substd. by (1-6) G20)
G20 = CO2H / CONH2
Derivative: or pharmaceutically acceptable addition salts
Patent location: claim 8

L71 ANSWER 92 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 119:159867 MARPAT <<LOGINID::20061024>>

TITLE: Phenol derivatives as agonists of a cyclic AMP-dependent protein kinase

INVENTOR(S): Porter, Roderick Alan; Prain, Hunter Douglas; Murray, Kenneth John; Warrington, Brian Herbert

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9310107	A1	19930527	WO 1992-GB2119	19921116
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9229274	A1	19930615	AU 1992-29274	19921116
EP 620815	A1	19941026	EP 1992-923480	19921116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07503235	T2	19950406	JP 1992-509095	19921116
ZA 9208894	A	19940518	ZA 1992-8894	19921118
PRIORITY APPLN. INFO.:			GB 1991-24579	19911120
			WO 1992-GB2119	19921116

GI



AB The title compds. I (Ar = Ph, substituted phenyl; R = HO or bioprecursor; R1 = tetrazolyl, carboxyalkyl, etc.) and their uses as pharmaceuticals are claimed. I are cyclic adenosine monophosphate-dependent protein kinase antagonists. I are potentially useful as antiproliferative agents, blood platelet aggregation inhibitors, smooth muscle relaxants, bronchodilators, antiallergics, inflammation inhibitors, antihypercholesteremics, and for treatment of irritable bowel syndrome (no data). Treatment of 2-hydroxy-4-(2,3-dipropoxyphenyl)benzonitrile with sodium azide/ammonium chloride in N-methylpyrrolidinone gave 2-(5-tetrazolyl)-5-(2,3-dipropoxyphenyl)phenol (II). The pharmacol. activity of II was not tested. Also prepared was Et 2-hydroxy-4-(2,3-dipropoxyphenyl)phenyl phosphonate (III).

MSTR 1



G11 = Ph (opt. substd. by (1-3) G12)
G12 = alkyl <containing 1-6 C> (opt. substd. by G15)
G15 = 53



G16 = OH / NH2
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1

MSTR 2



G11 = Ph (opt. substd. by (1-3) G12)
G12 = alkyl <containing 1-6 C> (opt. substd. by G15)
G15 = CO2H / 53



G16 = NH2
Patent location: claim 10

MSTR 4



G11 = Ph (opt. substd. by (1-3) G12)
G12 = alkyl <containing 1-6 C> (opt. substd. by G15)
G15 = CO2H / 53

C(O)-G16
53

G16 = NH2
Patent location: claim 10

MSTR 6



G11 = Ph (opt. substd. by (1-3) G12)
G12 = alkyl <containing 1-6 C> (opt. substd. by G15)
G15 = CO2H / 53

C(O)-G16
53

G16 = NH2
Patent location: claim 10

L71 ANSWER 93 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 119:139256 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of substituted quinazolines as angiotensin II antagonists
INVENTOR(S): Primeau, John L.; Garrick, Lloyd M.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5187168	A	19930216	US 1991-782850	19911024
US 5236925	A	19930817	US 1992-927032	19920806
WO 9308170	A1	19930429	WO 1992-US8991	19921023
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9331227	A1	19930521	AU 1993-31227	19921023
EP 612317	A1	19940831	EP 1992-925018	19921023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
JP 07500344	T2	19950112	JP 1992-507898	19921023
US 5256781	A	19931026	US 1993-34030	19930322
PRIORITY APPLN. INFO.:			US 1991-782850	19911024
			US 1992-927032	19920806
			WO 1992-US8991	19921023

GI



I

AB Title compds. I (A, Z = O, S, imino, CR7:CR8; R7, R8 = H, alkyl alkoxyalkyl, HO2C, halo, perfluoroalkyl, aralkyl, NC, O2N, etc.; X = H, halo, perfluoroalkyl, alkoxyalkyl, R9R10N, carbamoyl(alkyl), etc.; R9, R10 = H, alkyl, alkoxyalkyl, aralkyl, Y = R13N, etc.; R13 = H, alkyl, perfluoroalkyl, etc.; R1 = 5-tetrazolyl, HO3S, HO2C, MeSO2NH, etc.; R2-R4 = R7; R5 = alkyl, halo, alkyl, HO, R9R10N, NC, etc.) or a salt thereof, are prepared 4,2-Cl(O2N)C6H3CONH2 (preparation given) was reduced to the amino derivative, treated with F3CCONH2 to give 7-chloro-2-trifluoromethyl-4-quinazolone, chlorinated with POCl3, and the dichloro derivative was treated with 4'-(aminomethyl-1,1'-biphenyl-2-carboxylic acid to give I (A = Z = CH:CH, X = F3C, Y = NH, R = HO2C R2 = R3 = R4 = H, R5 = 8-Cl). A similar prepared compound I (A = S, Z = CH:CH2, X = F3C, Y = NH, R1 = NaO2C, R2 = R3 = R4 = R5 = H) at 10 mg/kg i.d. lowered the angiotensin II-dependent blood pressure by .apprx.45% at 1/2 h post administration.

MSTR 1C



G6 = 40 / 42



G7 = (1-3) CH2
G8 = 54-7 55-12



G10 = 76 / 78

G12 = 83-15 82-23 81-22



Derivative: or pharmaceutically acceptable salts, solvates, and hydrates
Patent location: claim 1

MSTR 2



G6 = 40 / 42



G8 = 54-7 55-12



G10 = 76



G12 = 83-15 82-23 81-22



G17 = alkylidene (opt. substd. by 1 or more G10)
G20 = 179-12 180-15



Derivative: or pharmaceutically acceptable salts, solvates, and hydrates
Patent location: disclosure

Note: substitution is restricted

L71 ANSWER 94 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 117:100829 MARPAT <<LOGINID::20061024>>
TITLE: Method for forming photographic images by using silver dye bleach method
INVENTOR(S): Laver, Hugh Stephen; Leppard, David G.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 465412	A1	19920108	EP 1991-810473	19910619
R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
CA 2045718	AA	19911229	CA 1991-2045718	19910626
JP 04233534	A2	19920821	JP 1991-183549	19910628
PRIORITY APPLN. INFO.:			CH 1990-2150	19900628
			CH 1990-3052	19900920

GI



AB The title method comprises exposure of the photog. material in presence of a phenolic stabilizer X(Y)n [n = 1, 2, 4; Y = I where R1, R2 = H, OH; R3, R4 = R1, halogen, alkyl, alkoxy, Ph, phenoxy, naphthyl, naphthoxy, OCOR8 (R8 = alkyl, alkenyl, benzyl; X (when n = 1) = H, R10QCO(CH2)m, R10C(:NR11), R10SO, R10SO2, II (m = 0-3; R10 = H, alkyl, alkenyl, phenylalkyl, naphthyl, substituted Ph; Q = bond, O, NR9, OCO; R11 = H, alkyl, Ph, benzyl; R14 = H, alkyl, halogen, alkoxy; R9 = H, alkyl); X (when n = 2) = CO, SO, SO2, :C:NR11, ((CH2)mCO)2Z, R18 (R18 = alkylene, alkenylene, alkinylene, phenylene, -p-C6H4-CMe3-p-C6H4-; Z = direct bond, alkylene, phenylene, etc.; X (when n = 4) = C((CH2)mCO2(CH2)m)4-]. The material shows improved color d. retention.

MSTR 1B



G1 = phenylene (substd. by 1 or more G2)
G3 = alkyl <containing 1-18 C> (opt. substd. by G5)
G5 = CO2H / 14



G16 = phenylene
Patent location: claim 2

L71 ANSWER 95 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 115:159796 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of α-amino acids
INVENTOR(S): Mizuno, Tadashi; Tabei, Nobuaki; Okamura, Haruki; Oosu, Motomasa
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03093756	A2	19910418	JP 1989-231163	19890905

PRIORITY APPLN. INFO.: JP 1989-231163 19890905
OTHER SOURCE(S): CASREACT 115:159796
AB α-Amino acids are prepared by liquid-phase hydrolysis of H2NCR1R2CONH2 [R1,R2 = H, cyclohexyl, (substituted) lower alkyl or Ph] by contacting with H2O in presence of Zn(OH)2. A mixture containing H2NCH(CONH2)CH2CH2SMe, H2O, and Zn(OH)2 was autoclaved at 140° for 2 h to give 88% methionine, vs. 10% without Zn(OH)2.

MSTR 1



G1 = 10



G2 = alkyl <containing 1-4 C>

(opt. substd. by 1 or more G4)
G3 = Ph (opt. substd. by 1 or more G4)
G4 = CO2H / Ph (opt. substd. by 1 or more OH)
Patent location: claim 1

L71 ANSWER 96 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 115:159795 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of α-amino acids
INVENTOR(S): Mizuno, Tadashi; Tabei, Nobuaki; Okamura, Haruki; Nagai, Koichi; Oosu, Motomasa
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03093755	A2	19910418	JP 1989-231162	19890905

PRIORITY APPLN. INFO.: JP 1989-231162 19890905
OTHER SOURCE(S): CASREACT 115:159795
AB α-Amino acids are prepared by liquid-phase hydrolysis of H2NCR1R2CONH2 [R1,R2 = H, cyclohexyl, (substituted) lower alkyl or Ph] by contacting with H2O in presence of heteropoly acids or their salts. A mixture containing H2NCH(CONH2)CH2CH2SMe, H2O, and ammonium cesium molybdophosphate (I) was autoclaved at 140° for 2 h to give 94% methionine, vs. 10% without I.

MSTR 1



G1 = 10



G2 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G4)
G3 = Ph (opt. substd. by 1 or more G4)
G4 = CO2H / Ph (opt. substd. by 1 or more OH)
Patent location: claim 1

L71 ANSWER 97 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 115:159794 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of α-amino acids

INVENTOR(S): Mizuno, Tadashi; Tabei, Nobuaki; Okamura, Haruki; Yoshioka, Hiroshi; Oosu, Motomasa
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03093754	A2	19910418	JP 1989-229726	19890904

PRIORITY APPLN. INFO.: JP 1989-229726 19890904
OTHER SOURCE(S): CASREACT 115:159794

AB α-Amino acids are prepared by liquid-phase hydrolysis of H2NCR1R2CONH2 [R1,R2 = H, cyclohexyl, (substituted) lower alkyl or Ph] by contacting with H2O in the presence of compound metal oxides. An aqueous solution of Nb2O5 was treated dropwise with Ti(OCHMe2)4 to give a precipitated double hydroxide, which was calcined 6 h at 300° to afford TiO2-Nb2O5 catalyst. Then, H2NCH(CONH2)CH2CH2SMe, H2O, and the catalyst were autoclaved at 140° for 2 h to give 94% methionine, vs. 10% without the catalyst.

MSTR 1



G1 = 10



G2 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G4)
G3 = Ph (opt. substd. by 1 or more G4)
G4 = CO2H / Ph (opt. substd. by 1 or more OH)
Patent location: claim 1

L71 ANSWER 98 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 115:159793 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of α-amino acids
INVENTOR(S): Mizuno, Tadashi; Tabei, Nobuaki; Okamura, Haruki; Sato, Hiroshi; Oosu, Motomasa; Too, Yasuhiko
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03093753	A2	19910418	JP 1989-229725	19890904

PRIORITY APPLN. INFO.: JP 1989-229725 19890904
OTHER SOURCE(S): CASREACT 115:159793
AB α-Amino acids are prepared by liquid-phase hydrolysis of H2NCR1R2CONH2 [R1,R2 = H, cyclohexyl, (substituted) lower alkyl or Ph] by contacting with H2O in presence of ZrO2, TiO2, and/or Nb2O5. A mixture containing H2NCH(CONH2)CH2CH2SMe, H2O, and ZrO2 was autoclaved at 140° for 2 h to give 94% methionine, vs. 10% without ZrO2.

MSTR 1



G1 = 10



G2 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G4)
G3 = Ph (opt. substd. by 1 or more G4)
G4 = CO2H / Ph (opt. substd. by 1 or more OH)
Patent location: claim 1

L71 ANSWER 99 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 115:92272 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives as aromatase inhibitors
INVENTOR(S): Greco, Michael N.; Janssen, Marcel August Constant
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 426225	A2	19910508	EP 1990-202751	19901016
EP 426225	A3	19911009		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

US 5066656	A	19911119	US 1990-580393	19900910
CA 2026792	AA	19910502	CA 1990-2026792	19901003
JP 03153686	A2	19910701	JP 1990-284509	19901024
PRIORITY APPLN. INFO.:			US 1989-430030	19891101

GI



I



II



III

AB Title compds. [I; R1 = H, NO2, amino, halo, alkyl, OH, alkoxy; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, bicyclo[2.2.1]heptan-1-yl, 2,3-dihydro-1H-indenyl, 1,2,3,4-tetrahydronaphthalenyl, (substituted) Ph, OR3, alkyl substituted with phenylalkyl, naphthalenyl, thienyl, furyl, alkylfuryl, cycloalkyl, OH, or alkoxy; R3 = H, (substituted) alkyl, alkenyl, phenylalkyl, alkynyl, pyrimidinyl, PH2C, alkylpiperidin-4-yl; n = 0,1], were prepared Thus, phenylenediamine II in 5 N HCl at 0° was treated with NaNO2 to gtive 43.5% title compound III. I at 1 mg/kg s.c. in female rats gave 80-98% aromatase inhibition. Several I are said to show reduced hepatotoxicity relative to prior art compds.

MSTR 1A



G1 = bond
G6 = alkyl <containing 1-10 C>
(opt. substd. by 1 or more G8)
G8 = CONH2 / CO2H / 77

p-C_6H_4Ph

Derivative: or pharmaceutically acceptable acid addition salts
Patent location: claim 1
Stereochemistry: or stereochemically isomeric forms

L71 ANSWER 100 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 114:185252 MARPAT <<LOGINID::20061024>>
TITLE: Preparation of (thienylalkyl) urea derivative as lipoxygenase inhibiting compounds
INVENTOR(S): Brooks, Dee W.; Stewart, Andrew O.; Summers, James B.; Kerkman, Daniel J.; Martin, Jonathan G.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9012008	A1	19901018	WO 1990-US1488	19900320
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2050597	AA	19901001	CA 1990-2050597	19900320
JP 04504261	T2	19920730	JP 1990-506101	19900320
EP 588785	A1	19940330	EP 1990-906504	19900320
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
US 5185363	A	19930209	US 1991-768621	19910930
PRIORITY APPLN. INFO.:			US 1989-331566	19890330
			US 1986-856725	19860425
			US 1987-42491	19870424
			WO 1990-US1488	19900320

GI



II



III



IV

AB R1R2NC(Z)N(OM)XR3 [I; R1, R2 = H, (substituted) C1-6 alkyl, OH; R3 = (substituted) Ph, naphthyl, thienyl, etc.; M = H, cation, aroyl, etc.; X = (substituted) C1-6 alkylene, C2-6 alkenylene, etc.; Z = O, S], useful as 5- and 12-lipoxygenase inhibitors in treatment of inflammatory diseases, etc., are prepared To a stirred solution of 5.0 g acetylthiophene derivative (II; Z1 = O) in 1:1 EtOH-pyridine was added H2NOH.HCl with stirring to give quant. oxime (II; Z1 = NOH), which (5.5 g) was reduced with BH3-pyridine in EtOH to give 2.2 g hydroxylamine derivative III. To a stirred solution of 2.2

g III in THF was added Me3SiNCO, followed by saturated NH4Cl to give 1.7 g urea derivative IV, which showed IC50 of 0.53 + 10-6M in vitro against 5-lipoxygenase and 94% inhibition of in vivo leukotriene biosynthesis at 200 μmol/kg orally in rats. Also prepared and tested were 157 addnl. I.

MSTR 1A



G2 = alkylene <containing 1-6 C>
(opt. substd. by 1 or more G3)
G3 = 24

C(O)-G17
24

G4 = 7

G5—G6
7

G5 = 9

N—G21
9

G7 = 24

C(O)-G17
24

G8 = 30

G22—G23
30

G17 = NH2 / OH
G19 = 24

C(O)-G17
24

G21 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G7) /
aryl (opt. substd. by 1 or more G19)
G22 = phenylene
G23 = Ph (opt. substd. by 1 or more G13)
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1

L71 ANSWER 101 OF 101 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 113:211849 MARPAT <<LOGINID::20061024>>
TITLE: Arylalkylpiperidines and -piperazines as antihypertensives
INVENTOR(S): Syoji, Masataka; Toyota, Kozo; Eguchi, Chikahiko; Domoto, Hideki; Yoshimoto, Ryota; Kamimura, Akira
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 370712	A2	19900530	EP 1989-311961	19891117
EP 370712	A3	19911002		
R: CH, DE, FR, GB, IT, LI				
JP 02262541	A2	19901025	JP 1989-26232	19890203
PRIORITY APPLN. INFO.:			JP 1988-293408	19881118
			JP 1988-303461	19881130
			JP 1989-26232	19890203
			JP 1989-64059	19890316

GI



II

AB QXCH2CH2N(Z)CH2CH2YW[I; Q = PhO, 4-F3CC6H4, 2-O2NC6H4, 2-H2NC6H4, 2-EtO2CNHC6H4, naphthyl, etc.; X = (substituted) (heteroatom-interrupted) alkylene, alkenylene; Z = Me; W = H; ZW = CH2CH2; Y = PhCOCH, 4-FC6H4COCH, 4-FC6H4CON, PhN, 4-FC6H4 CH:C Ph2CHN, 4-FC6H4 SO2N, etc.], were prepared Thus, 3,4-(MeO)2C6H3CH2CN in dimethoxyethane (DME) was added dropwise to NaNH2 in DME at room temp; the mixture was then stirred at 50° for 1 h and Br(CH2)9Me in DME was added at room temperature The mixture was stirred in 1 h at room temperature and 2 h at 50°, cooled, treated with NaNH2, stirred 2 h at 50°, cooled, treated with Br(CH2)3Cl in DME, stirred 1 h at room temperature and 2 h at 50° to give 3,4-

(MeO)2C6H3C[(CH2)9Me][(CH2)3Cl]CN. The latter was refluxed with 4-(4-fluorobenzoyl)piperidine.HCl, K2CO3, and NaI in MeCOCH2CHMe2 overnight to give II. I at 10 mg/kg i.v. in rats reduced blood pressure by up to 135 mm Hg 30 min after administration.

MSTR 1A



G1 = carbon chain (opt. substd. by 1 or more G17)
G17 = 119



G18 = 121



G19 = OH (opt. substd.) / NH2
G20 = Ph
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1

MSTR 1M



G1 = carbon chain (opt. substd. by 1 or more G17)
G17 = 119



G18 = 121



G19 = OH (opt. substd.) / NH2
G20 = Ph
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1